InflaRx Set to Launch Phase 2 Trial Testing IFX-1 in AAV Patients Following FDA Approval
InflaRx will soon begin a Phase 2 clinical trial assessing the safety and effectiveness of IFX-1 — an inhibitor of the complement system — in patients with ANCA-associated vasculitis (AAV). This follows the the U.S. Food and Drug Administration’s approval of the company’s investigational new drug application (IND). The Phase…